Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin, Paclitaxel +/- Sorafenib in Advanced Melanoma
NCT00110019Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2005
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Arm I (paclitaxel, carboplatin, sorafenib tosylate) with Arm II (carboplatin, paclitaxel, placebo) (2 arms). Primary endpoint: Overall Survival. Started Jun 2005; status: completed.
02
Drugs
sorafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00110019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00110019.